LA Cancer Challenge 5K to Support Targeted Cancer Care

The upcoming October 25 race at UCLA raises funds for research into targeted therapies for patients like Federico Kalinec.

Updated on Oct. 21, 2026 in Cancer

Gouache-painted illustration of athletic shoes on a running track, evoking the supportive spirit of community-based health research initiatives. — The LA Cancer Challenge 5K returns to UCLA on October 25 to raise funds for underfunded pancreatic neuroendocrine tumor research initiatives. AI Illustration. Upload story photo >

Federico Kalinec, a pancreatic neuroendocrine tumor survivor, is participating in the LA Cancer Challenge 5K on October 25, 2026, at UCLA. This event raises funds for research into targeted treatments for this underfunded cancer diagnosis.

Why it matters

Pancreatic neuroendocrine tumors remain a significantly underfunded area of oncology, making charitable support for research into new targeted therapies crucial. Increased funding aims to expand access to innovative treatments like those that have supported long-term survivors.

This case involves a patient managing a recurrence of a pancreatic neuroendocrine tumor diagnosed 14 years ago, illustrating the impact of targeted intervention. The use of peptide receptor radionuclide therapy remains a focus for clinical investigation.

The players

Federico Kalinec

A long-term survivor of pancreatic neuroendocrine tumors who advocates for cancer research.

Hirshberg Foundation for Pancreatic Cancer Research

A charitable organization that funds research initiatives and grants for targeted pancreatic cancer treatments.

The details

Peptide receptor radionuclide therapy works by delivering radioactive atoms directly to tumor cells, which are identified using advanced PET scans to ensure precision. This targeted approach allows the treatment to attack cancer cells while minimizing damage to surrounding healthy tissue. The Hirshberg Foundation funds the PNET Pathway Grant Program to advance these types of targeted molecular therapies for patients.

2012: Federico Kalinec receives his initial pancreatic neuroendocrine tumor diagnosis.
2020: Kalinec experiences a recurrence of his cancer.
October 25, 2026: The LA Cancer Challenge 5K takes place at UCLA.

Health Landscape

The PNET Pathway Grant Program functions as a benchmark for funding in a typically under-resourced oncological field, providing a template for future targeted treatment research. Local advocacy efforts are increasingly aligning with these focused initiatives to accelerate the development of precision therapies.

Patients dealing with neuroendocrine tumors should discuss the suitability of peptide receptor radionuclide therapy with their oncology team. It is also important for those with a history of pancreatic cancer to monitor symptom patterns closely through regular follow-up screenings at specialized centers.

The takeaway

Targeted therapies like peptide receptor radionuclide therapy continue to evolve as a key management strategy for neuroendocrine tumors. Patients should work with their physicians to track new clinical trials and treatment protocols that match their specific diagnosis.